Ani Pharmaceuticals (ANIP) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $26.6 million.
- Ani Pharmaceuticals' Income towards Parent Company rose 21007.2% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 67156.96%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
- Per Ani Pharmaceuticals' latest filing, its Income towards Parent Company stood at $26.6 million for Q3 2025, which was up 21007.2% from $8.5 million recorded in Q2 2025.
- Over the past 5 years, Ani Pharmaceuticals' Income towards Parent Company peaked at $26.6 million during Q3 2025, and registered a low of -$24.2 million during Q3 2024.
- Over the past 5 years, Ani Pharmaceuticals' median Income towards Parent Company value was -$2.3 million (recorded in 2024), while the average stood at -$2.1 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 1837272.73% in 2022, then soared by 113521.03% in 2024.
- Quarter analysis of 5 years shows Ani Pharmaceuticals' Income towards Parent Company stood at -$24.1 million in 2021, then surged by 82.35% to -$4.3 million in 2022, then surged by 127.12% to $1.2 million in 2023, then crashed by 989.7% to -$10.3 million in 2024, then surged by 358.86% to $26.6 million in 2025.
- Its Income towards Parent Company stands at $26.6 million for Q3 2025, versus $8.5 million for Q2 2025 and $15.7 million for Q1 2025.